• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Immunome Inc.

    3/3/26 4:22:42 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMNM alert in real time by email
    S-8 1 imnm-20260303.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 3, 2026

    Registration No. 333-

     

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    IMMUNOME, INC.

    (Exact name of registrant as specified in its charter)

    Delaware

    77-0694340

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

    18702 N. Creek Parkway, Suite 100

    Bothell, WA 98011

    (Address of Principal Executive Offices)

     

    Immunome, Inc. 2020 Equity Incentive Plan

    Immunome, Inc. 2020 Employee Stock Purchase Plan

    Immunome, Inc. 2024 Inducement Plan

    (Full titles of the plans)

    Clay Siegall, Ph.D.

    Chief Executive Officer

    Immunome, Inc.

    18702 N. Creek Parkway, Suite 100

    Bothell, WA 98011

    (425) 939-7410

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Thomas A. Coll, Esq.

    Carlos Ramirez, Esq.

    Dylan Kornbluth, Esq.

    Cooley LLP

    10265 Science Center Drive

    San Diego, California 92121

    Tel: (858) 550-6000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

     

    Accelerated filer

    ☐

     

     

     

     

     

    Non-accelerated filer

    ☒

     

    Smaller reporting company

    ☐

     

     

     

     

     

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    EXPLANATORY NOTE

    This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the registrant on Form S-8 relating to the same employee benefit plans are effective.

    The registrant previously registered shares of its Common Stock for issuance under its 2020 Equity Incentive Plan (the “2020 Plan) and 2020 Employee Stock Purchase Plan (the “2020 ESPP”) under Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on March 25, 2021 (File No. 333-254731), March 16, 2023 (File No. 333-270598), and February 2, 2024 (File No. 333-276839). Additionally, the registrant previously registered shares of its Common Stock for issuance under its 2020 Plan, 2020 ESPP and 2024 Inducement Plan under a Registration Statement on Form S-8 filed with the Commission on March 19, 2025 (File No. 333-285930). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    (a)
    The registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 3, 2026;
    (b)
    The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K from the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 24, 2025; and
    (c)
    The description of the Registrant’s Common Stock set forth in the Registration Statement on Form 8-A filed with the Commission on September 30, 2020, including any amendments or reports filed for the purpose of updating such description.

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information, or portions thereof, which are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     


     

    Item 8. Exhibits.

     

    Exhibit
    Number

     

    Description

     

     

     

    4.1

    Amended and Restated Certificate of Incorporation of the Registrant (Filed as Exhibit 3.1 to Registrant’s Current Report on Form 8-K filed with the Commission on October 6, 2020 and incorporated herein by reference).

     

     

     

    4.2

     

    Certificate of Amendment, dated October 2, 2023 to the Amended and Restated Certificate of Incorporation of Immunome, Inc. to implement Officer Exculpation (Filed as Exhibit 3.3 to the Registrant’s Current Report on Form 8-K filed with the Commission on October 4, 2023 and incorporated herein by reference).

     

     

     

    4.3

     

    Certificate of Amendment, dated October 2, 2023 to the Amended and Restated Certificate of Incorporation of Immunome, Inc. to implement the Authorized Share Increase (Filed as Exhibit 3.4 to the Registrant’s Current Report on Form 8-K filed with the Commission on October 4, 2023 and incorporated herein by reference).

     

     

     

    4.4

    Amended and Restated Bylaws of the Registrant (Filed as Exhibit 3.2 to Registrant’s Current Report on Form 8-K filed with the Commission on October 6, 2020 and incorporated herein by reference).

     

     

     

    4.5

     

    Form of Common Stock Certificate (Filed as Exhibit 4.2 to Amendment No. 1 to Registrant’s Registration Statement on Form S-1/A filed on September 24, 2020 and incorporated herein by reference).

     

     

     

    5.1*

    Opinion of Cooley LLP.

     

     

     

    23.1*

    Consent of Independent Registered Public Accounting Firm.

     

     

     

    23.2*

    Consent of Cooley LLP (included in Exhibit 5.1).

     

     

     

    24.1*

    Power of Attorney (included on signature page).

     

     

     

    99.1+

     

    2020 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on November 9, 2023).

     

     

     

    99.2+

     

    Forms of Executive and Non-Executive Stock Option Grant Notice, Option Agreement and Notice of Exercise for the 2020 Equity Incentive Plan (Filed as Exhibit 10.7 to Registrant’s Annual Report on Form 10-K filed with the Commission on March 19, 2025 and incorporated herein by reference).

     

     

     

    99.3+

     

    Immunome, Inc. 2024 Inducement Plan, as amended, and Forms of Executive and Non-Executive Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder (incorporated by reference in Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on August 6, 2025).

     

     

     

     

    99.4+

     

    Immunome, Inc. 2020 Employee Stock Purchase Plan (Filed as Exhibit 10.8 to Amendment No. 1 to Registrant’s Registration Statement on Form S-1/A filed with the Commission on September 24, 2020 and incorporated herein by reference).

     

     

     

    107*

    Filing Fee Table.

     

    * Filed herewith.

    + Denotes management contract or compensatory plan or arrangement.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bothell, State of Washington, on March 3, 2026.

     

    IMMUNOME, INC.

     

     

    By:

     

    /s/ Clay Siegall

     

     

    Clay Siegall, Ph.D.

     

     

    Chief Executive Officer

     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Clay Siegall, Ph.D. and Max Rosett, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature

    Title

    Date

     

     

     

    /s/ Clay Siegall

    President, Chief Executive Officer and Chairman of the Board of Directors

    March 3, 2026

    Clay Siegall, Ph.D.

     

    (Principal Executive Officer)

     

     

     

     

     

     

    /s/ Max Rosett

    Chief Financial Officer

    March 3, 2026

    Max Rosett

     

    (Principal Financial and Accounting Officer)

     

     

     

     

     

     

    /s/ Isaac Barchas

    Director

    March 3, 2026

    Isaac Barchas

     

     

     

     

     

     

     

    /s/ Jean-Jacques Bienaimé

     

    Director

     

    March 3, 2026

    Jean-Jacques Bienaimé

     

     

     

     

     

    /s/ James Boylan

    Director

    March 3, 2026

    James Boylan

     

     

     

     

     

     

     

    /s/ Carol Schafer

    Director

    March 3, 2026

    Carol Schafer

     

     

     

     

     

     

     

    /s/ Sandra M. Swain

    Director

    March 3, 2026

    Sandra M. Swain, M.D.

     

     

     

     

     

     

     

    /s/ Philip Wagenheim

    Director

    March 3, 2026

    Philip Wagenheim

     

     

     

     


    Get the next $IMNM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMNM

    DatePrice TargetRatingAnalyst
    5/28/2026$36.00Overweight
    Barclays
    2/12/2026$40.00Buy
    H.C. Wainwright
    12/1/2025$36.00Buy
    Truist
    9/22/2025$26.00Buy
    Goldman
    9/5/2025$26.00Buy
    Craig Hallum
    4/2/2025$23.00Buy
    Lake Street
    11/8/2024$30.00Overweight
    Stephens
    5/31/2024$27.00Overweight
    Piper Sandler
    More analyst ratings

    $IMNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Immunome with a new price target

    Barclays initiated coverage of Immunome with a rating of Overweight and set a new price target of $36.00

    5/28/26 8:56:32 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Immunome with a new price target

    H.C. Wainwright initiated coverage of Immunome with a rating of Buy and set a new price target of $40.00

    2/12/26 7:24:43 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Immunome with a new price target

    Truist initiated coverage of Immunome with a rating of Buy and set a new price target of $36.00

    12/1/25 8:29:07 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bienaime Jean Jacques bought $103,500 worth of shares (5,000 units at $20.70), increasing direct ownership by 13% to 43,415 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    5/19/26 7:56:51 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Higgins Jack

    4 - Immunome Inc. (0001472012) (Issuer)

    4/3/26 7:48:14 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Rosett Max

    4 - Immunome Inc. (0001472012) (Issuer)

    4/3/26 7:46:52 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bienaime Jean Jacques bought $103,500 worth of shares (5,000 units at $20.70), increasing direct ownership by 13% to 43,415 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    5/19/26 7:56:51 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bienaime Jean Jacques bought $43,670 worth of shares (2,000 units at $21.84), increasing direct ownership by 5% to 38,415 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    3/12/26 6:05:05 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Siegall Clay B bought $100,018 worth of shares (4,729 units at $21.15), increasing direct ownership by 0.72% to 665,254 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/30/25 6:47:24 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.

    SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject)

    5/15/26 4:15:59 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.

    SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject)

    5/15/26 10:06:33 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Immunome Inc.

    10-Q - Immunome Inc. (0001472012) (Filer)

    5/12/26 4:10:34 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting

    Varegacestat treatment resulted in statistically significant improvements in primary and all key secondary efficacy endpoints Varegacestat demonstrated statistically significant improvement in worst pain intensity at week 12, with a clinically significant difference observed as early as the first evaluation at week 4 Progression-free survival benefit was consistent across prespecified patient subgroups, including tumor location, baseline tumor size, patient age and prior systemic desmoid tumor therapy New Drug Application (NDA) for varegacestat submitted to the U.S. Food and Drug Administration (FDA) in April 2026, with Marketing Authorization Application (MAA) submission to the E

    5/30/26 8:00:00 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

    Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 10:40 a.m. EDT. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days. About Immunome, Inc. Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-

    5/27/26 8:00:00 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

    New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) in April 2026 seeking approval of varegacestat for the treatment of adults with desmoid tumors Detailed Phase 3 RINGSIDE data selected for oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Phase 1 study ongoing for IM-1021, with initial lymphoma data expected in 2026 Investigational New Drug (IND) clearance received in April 2026 for IM-1617, a potential first-in-class solid tumor antibody-drug conjugate (ADC) Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announ

    5/12/26 4:02:00 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNM
    Leadership Updates

    Live Leadership Updates

    View All

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer

    Co-founder Susan Dillon, Ph.D., to remain as the chair of Board of Directors Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) medicines, today announced that its co-founder, Susan Dillon, Ph.D., will transition from her position as president and chief executive officer (CEO) and continue as chair of the Board of Directors and advisor to the company. As part of the planned leadership transition, Aro appointed industry veteran Purnanand Sarma, Ph.D., as the CEO and a member of the Board, effective immediately. "We founded Aro with the vision to create a new class of targeted siRNA medicines to address significant

    2/11/25 8:30:00 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunome Appoints Roee Shahar as Executive Vice President, Commercial

    Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Company. "Roee further strengthens an Immunome team whose members have designed, developed and commercialized innovative targeted therapies for cancer patients," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.

    10/8/24 8:05:00 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immunome Inc.

    SC 13G/A - Immunome Inc. (0001472012) (Subject)

    11/14/24 9:00:58 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Immunome Inc.

    SC 13G - Immunome Inc. (0001472012) (Subject)

    11/14/24 1:28:33 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Immunome Inc.

    SC 13G - Immunome Inc. (0001472012) (Subject)

    11/14/24 10:33:51 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNM
    Financials

    Live finance-specific insights

    View All

    Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

    Registrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16, p<0.0001) Trial also met all key secondary endpoints, with varegacestat delivering an objective response rate of 56% Varegacestat was generally well tolerated with a manageable safety profile New Drug Application submission to U.S. FDA planned for Q2 2026 Company to host conference call today at 8:30 a.m. ET Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacest

    12/15/25 7:00:00 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

    Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, in patients with progressing desmoid tumors. Webcast, Presentation Slides and Conference Call Information Immunome will host a webcast and conference call on Monday, December 15, 2025, at 8:30 a.m. ET / 5:30 a.m. PT to disc

    12/14/25 4:00:00 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates (AICsTM) For Cancer Treatment

    - IsoBio, Inc. (IsoBio) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates (AICsTM), targeting both derisked and novel tumor antigens for patients in need of new cancer therapies. - IsoBio has closed its initial Series Seed financing round, raising $5 million from ASP Isotopes Inc. (ASPI). - The strategic collaboration contemplates future manufacturing opportunities for PET Labs (ASPI's nuclear medicine subsidiary). - IsoBio plans to leverage the technology and global manufacturing capabilities developed by ASPI to reduce the uncertainty of isotope supply chain/manufacturi

    7/28/25 8:31:17 AM ET
    $ASPI
    $IMNM
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care